BRCA 1/2 germline mutations are common genetic alterations in breast cancer, but there are no FDA-approved BRCA 1/2-directed therapies in HER2-amplified breast cancers, as HER2-amplified breast cancer with BRCA mutations were typically excluded from the trials. Here, ERBB2 is linked to breast carcinoma.